Skip to main content

Completed Studies

  • A 12-week, randomized, double-blind, controlled evaluation followed by an open-label 12-week follow-up period of the impact of a psychotropic on response to psychotropic treatment in outpatients suffering from a major depressive disorder (MDD) and having had - within the current episode - an inadequate response to at least one psychotropic medication included in the psychotropic.
  • A prospective, longitudinal, observational study to evaluate potential predictors of relapse in subjects with major depressive disorder who have responded to antidepressant treatment.
  • Interventional, randomized, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose.
  • Study of vortioxetine in pediatric patients aged 12 to 17 years, with major depressive disorder (MDD).
  • An open-label, long-term extension safety study of drug in treatment-resistant depression.
  • Randomized, double-blind, multicenter, active-controlled study to evaluate the safety and tolerability of fixed doses of drug plus an oral antidepressant in subjects with treatment resistant depression.
  • Double-blind, placebo-controlled, proof-of-concept (POC) trial, a kappa-selective opioid receptor antagonist, augmentation of antidepressant therapy in treatment-resistant depression (TRD).
  • A phase 2 efficacy, safety, and tolerability study of study drug in subjects with schizophrenia and alcohol use disorder.
  • Open label extension for subjects with inadequate/partial response to antidepressants during the current episode of major depressive disorder previously treated with drug.
  • Phase 2, randomized, double-blind, multiple-dose level, placebo-controlled, single intravenous dose, parallel efficacy and safety study of study drug in subjects with major depressive disorder.
  • A 12-week, randomized, double-blind, controlled evaluation followed by an open-label 12-week follow-up period of the impact of genetic testing on response to psychotropic treatment in outpatients suffering from major depressive disorder (MDD).
  • Phase 2, double-blind, placebo-controlled, randomized withdrawal, parallel efficacy and safety study of study drug in subjects with inadequate/partial response to antidepressants during the current episode of major depressive disorder.
  • A placebo-controlled, double-blind, parallel-group, Bayesian adaptive randomization design and dose regimen-finding study to evaluate safety, tolerability and efficacy of study drug in subjects with Alzheimer's disease.
  • A randomized, double-blind, placebo-controlled, dose-ranging, parallel-group, phase 2 study of the safety and efficacy of study drug in the treatment of cognitive deficits in schizophrenia (CDS) in nonsmokers.
  • Long term safety and efficacy of study drug in subjects with schizophrenia: a double blind extension study.
  • A randomized, double-blind, placebo-controlled, parallel, 26-week, phase 3 study of 2 doses of study drug or placebo as an adjunctive pro-cognitive treatment in schizophrenia subjects on chronic stable atypical antipsychotic therapy.
  • 11-dehydroxy-thromboxane-b2 as a potential biomarker in bipolar depression.
  • A comparison of long-acting injectable medications for schizophrenia.
  • A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group efficacy and safety trial of study drug in subjects with mild to moderate Alzheimer's disease who are apoe4 non-carriers.
  • Phase 2, randomized, double-blind, multiple-dose level, placebo-controlled, single intravenous dose, parallel efficacy and safety study of study drug in subjects with inadequate/partial response to antidepressants during the current episode of major depressive disorder.
  • Study drug in patients with mild to moderate Alzheimer's disease.
  • A randomized, double-blind, placebo-controlled, parallel-group, study of the safety and efficacy of study drug in the treatment of cognitive deficits in schizophrenia (CDS).
  • A randomized, double-blind, placebo controlled study of the efficacy of lithium for the treatment of pediatric mania followed by an open label long-term safety period, double-blind, placebo-controlled discontinuation phase, and open label restabilization period.
  • A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of study drug in subjects with major depressive disorder.
  • A randomized, double blind, placebo controlled, intrasubject dose titration pilot study to determine the safety and maximum tolerated dose of drug in healthy volunteers.
  • A randomized, double-blind, placebo-controlled, parallel, 12-week, phase 2 study of two different doses of study drug or placebo in schizophrenia subjects on chronic stable atypical anti-psychotics.
  • A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety, and tolerability of study drug as augmentation therapy to improve cognition in outpatients with cognitive dysfunction in schizophrenia.
  • A randomized, double-blind, placebo-controlled, multi-center study of study drug as add-on therapy in outpatients with persistent negative symptoms of schizophrenia treated with a stable dose of a second generation antipsychotic.
  • A 4-week randomized, double-blind, parallel group, placebo controlled study to investigate the safety and efficacy of study drug as monotherapy in patients with treatment-resistant depression.
  • A double-blid, placebo-controlled, sponsor-open, randomized, multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of study drug in mild to moderate Alzheimer's disease patients on stable donepezil therapy.
  • A double-blind, randomized, placebo-controlled, multiple, escalating dose study to evaluate the safety, tolerability and pharmacokinetics of study drug in elderly volunteers and in subjects with mild Alzheimer's disease.
  • Comparative steady-state bioequivalence study of orally disintegrating tablets in patients with chronic or subchronic schizophrenia already taking clozapine.
  • A phase 1, open-label study to determine the effect of calories and fat content on the pharmacokinetics of repeated dose drug in patients with schizophrenia, schizoaffective, or schizophreniform disorder.
  • Pharmacokinetics of study drug following administration in subjects with varying degrees of impaired renal function.
  • A double-blind placebo-controlled preliminary study of the efficacy, safety and tolerability of study drug in the treatment of Alzheimer's disease.
  • A double-blind placebo-controlled preliminary study of the efficacy, safety and tolerability of study drug in the treatment of Alzheimer's disease in subjects currently receiving donepezil.
  • The use of metformin in the treatment of antipsychotic-induced weight gain in schizophrenia.
  • Combining medications to enhance depression outcomes.
  • Comparison of antipsychotics for metabolic problems study.
  • An open-label study to evaluate the prevalence of phenotypic poor metabolizers at cyp2d6 among venlafaxine-treated outpatients with depression.
  • Assessment of the EEG effects of bupropion hydrochloride.
  • Safety and tolerability of extended-release bupropion hydrochloride vs. bupropion hydrobromide.
Last modified: Oct 11, 2018
Contact Us

KU Wichita Center for Clinical Research

1010 N. Kansas
Wichita, KS 67214
Phone: 316-293-1833
Fax: 316-293-1829
Email: clinicaltrialunit@kumc.edu

Campus Map

Interested in joining a clinical trial?

Complete this form.

ID=x31955